

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal800mxz

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 Expanded CAPlus Coverage of US, Japanese, WIPO,  
EPO, and German patents  
NEWS 3 Dec 13 INFOR no longer available  
NEWS 4 Jan 18 ESBIODBASE - NEW FREE DISPLAY FORMATS, TRIAL  
FORMAT ENHANCED  
NEWS 5 Feb 1 Addition of Machine-Translated Abstracts to CAPlus  
NEWS 6 Feb 14 Homology Searching for Nucleotide Sequences in DGENE  
now available!

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:20:11 ON 14 FEB 2000

=> file .marykz

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 13:20:24 ON 14 FEB 2000

FILE 'AIDSLINE' ENTERED AT 13:20:24 ON 14 FEB 2000

FILE 'CAPLUS' ENTERED AT 13:20:24 ON 14 FEB 2000

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:20:24 ON 14 FEB 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:20:24 ON 14 FEB 2000  
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'JICST-EPLUS' ENTERED AT 13:20:24 ON 14 FEB 2000  
COPYRIGHT (C) 2000 Japan Science and Technology Corporation (JST)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'JAPIO' ENTERED AT 13:20:24 ON 14 FEB 2000  
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

=> s "oil in water" and submicron and emulsion

L1 142 "OIL IN WATER" AND SUBMICRON AND EMULSION

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 76 DUP REM L1 (66 DUPLICATES REMOVED)

=> s l2 and adjuvant

L3 5 L2 AND ADJUVANT

=> d 1-5 bib ab

L3 ANSWER 1 OF 5 MEDLINE

AN 96376087 MEDLINE

DN 96376087

TI MF59 **adjuvant** enhances the immunogenicity of influenza vaccine  
in both young and old mice.

AU Higgins D A; Carlson J R; Van Nest G

CS Chiron Corporation, Emeryville, CA 94608, USA.

SO VACCINE, (1996 Apr) 14 (6) 478-84.

Journal code: X60. ISSN: 0264-410X.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199705

AB The responses of young (8 week) and old (18 month) mice to influenza  
vaccine with and without the potent **emulsion adjuvant**  
MF59 were compared. In influenza naive mice, vaccine-specific antibody

and  
to T-cell proliferation were significantly lower in the old group compared  
to

the young group. Post-immunization cytokine levels and antibody isotype  
profiles were different in the old compared to the young mice. The  
addition of the **adjuvant** MF59, a **submicron oil**  
**-in-water emulsion** composed of 5% v/v squalene, 0.5%  
v/v Tween 80 and 0.5% v/v Span 85, significantly increased the immune  
responses of both the young and old naive mice to the vaccine. The  
responses of the old mice given **adjuvant** increased to levels  
equivalent to those of young mice with vaccine alone. In mice previously  
infected with influenza virus, similarly depressed immune responses to  
vaccination were detected in the old mice. While the addition of MF59 to  
the vaccine had little effect on antibody titres of the previously  
infected young mice, the **adjuvant** significantly increased the  
antibody responses of the previously infected old mice. These results  
suggest that influenza vaccine combined with MF59 may significantly  
improve immune responses of elderly humans to influenza vaccination.

L3 ANSWER 2 OF 5 MEDLINE  
 AN 96164471 MEDLINE  
 DN 96164471  
 TI Enhancement of humoral response against human influenza vaccine with the simple **submicron oil/water emulsion adjuvant** MF59.  
 AU Ott G; Barchfeld G L; Van Nest G  
 CS Chiron Corporation, Emeryville, CA 94608, USA.  
 SO VACCINE, (1995 Nov) 13 (16) 1557-62.  
 Journal code: X60. ISSN: 0264-410X.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199605  
 AB Human influenza subunit vaccines are not fully protective in either the very young or elderly populations where risk is greatest. The use of an **adjuvant** to enhance antibody titer is an attractive option to increase vaccine efficacy. A series of squalene/H2O emulsions stabilized either by the amphipathic muramyl peptide MTP-PE (sodium N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanyl-2-(1',2'-dipalmitoyl-sn-glycero-3'-phospho) ethylamide) or by mixtures of the sorbitan oleate surfactants Tween 80 and Span 85 have been tested as adjuvants with influenza vaccine. Combination of influenza vaccine with the Tween/Span stabilized emulsions has resulted in significantly higher antibody titers to vaccine in an extensive series of naive animal models. The use of **submicron emulsion** droplets is significant in determination of **adjuvant** activity while the presence of the muramyl peptide is not required for **adjuvant** activity. The 200-300 nm diameter **emulsion** formulation MF59 containing only the low toxicity components squalene, Tween 80 and Span 85 has been shown to enhance titers from 5 to 250 times that achievable with vaccine alone.

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2000 ACS  
 AN 1999:70411 CAPLUS  
 DN 130:129990  
 TI Use of **submicron oil-in-water** emulsions with DNA vaccines  
 IN McCormak, James E.; Jolly, Douglas J.; Van, Nest Gary  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902132	A2	19990121	WO 1998-US14310	19980708
	WO 9902132	A3	19990812		
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9882982	A1	19990208	AU 1998-82982	19980708
PRAI	US 1997-51944		19970708		
	US 1997-54756		19970805		
	WO 1998-US14310		19980708		
AB	The use of <b>submicron oil-in-water</b> emulsions				

with nucleic acid immunization techniques is disclosed. The method includes immunization with vaccine compns. contg. nucleic acid mols. encoding one or more antigens of interest, as well as administration of a **submicron oil-in-water adjuvant**, such as MF59. The **adjuvant** can be administered either before, after or simultaneously with the nucleic acid vaccines.

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2000 ACS

AN 1995:698952 CAPLUS

DN 123:93246

TI **Submicron** emulsions as vaccine adjuvants

IN Lowell, George H.; Amselem, Shimon; Friedman, Doron; Aviv, Haim

PA Pharmos Corp., USA

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511700	A1	19950504	WO 1993-US10402	19931029
	W: AT, AU, BB, BG, BR, BY, CA, CZ, DE, DK, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9455432	A1	19950522	AU 1994-55432	19931029
	US 5961970	A	19991005	US 1996-637756	19960429
	US 5985284	A	19991116	US 1996-677302	19960709
PRAI	WO 1993-US10402		19931029		
	US 1996-637756		19960429		

AB A vaccine **adjuvant** comprises an **oil-in-water submicron emulsion** that has 0.5-50% of an oil, 0.1-10% of an emulsifier, 0.5-5% of a nonionic surfactant, 0.00001-1% of an immunogen, and an aq. continuous phase. This **submicron emulsion** has a mean droplet size in the range of 0.03-0.5 .mu.m, and preferably 0.05-0.2 .mu.m.

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2000 ACS

AN 1991:542253 CAPLUS

DN 115:142253

TI **Adjuvant** formulation comprising a **submicron oil droplet emulsion**

IN Van Nest, Gary; Ott, Gary; Barchfeld, Gail

PA Chiron Corp., USA

SO Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 399843	A2	19901128	EP 1990-305744	19900525
	EP 399843	A3	19920902		
	EP 399843	B1	19940713		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2017507	AA	19901125	CA 1990-2017507	19900524
	CA 2017507	C	19961112		
	WO 9014837	A1	19901213	WO 1990-US2954	19900524
	W: HU, JP				
	HU 61203	A2	19921228	HU 1990-5459	19900524
	HU 212924	B	19961230		
	JP 05508385	T2	19931125	JP 1990-509214	19900524

JP 08032638	B4	19960329		
DD 294633	A5	19911010	DD 1990-341001	19900525
ES 2033626	T3	19941016	ES 1990-305744	19900525

PRAI US 1989-357035 19890525  
 WO 1990-US2954 19900524  
 OS MARPAT 115:142253  
 AB An **adjuvant** compn. comprises a metabolizable oil and an emulsifying agent in an **oil-in-water emulsion** having oil droplets <1 .mu.m in diam. Preferably, the emulsifying agent is also an immunostimulating agent, e.g. a lipophilic muramyl peptide. Alternatively, an immunostimulating agent sep. from the emulsifying agent can be used. Goats were immunized with herpes simplex virus gD2 antigen (recombinant glycosylated protein with truncated anchor region) in squalene 4% and MTP-PE  
 (N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-[1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy)]ethylamide) 500 .mu.g/mL. The oil droplets in the **emulsion** were 0.5-0.6 .mu.m.  
 This formulation gave the highest antibody titers.

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.13	18.28
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.67	-1.67

SESSION WILL BE HELD FOR 60 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 13:23:24 ON 14 FEB 2000